An intriguing study by Miquel Serra-Burriel et al. (2024) delves into the effects of genericization on drug prices in 8 high-income countries, including Australia, Canada, France, Germany, Japan, Switzerland, the UK, and the US. The researchers analyzed data from 2011-2020 IQVIA MIDAS on 505 novel originator drugs. Their findings revealed significant price decreases post-patent expiration, with the most rapid declines seen in the US at 32% (95% CI, 24%-39%) in the first year and 82% (95% CI, 71%-89%) by year 8. Other countries showed decreases ranging from 64% in Australia to 18% in Switzerland over the same period. A cost-effectiveness simulation model highlighted potential bias in incremental cost-effectiveness ratios ranging from 40% to -40% if generic entry is not considered.
For more details, refer to the full article.
Explore the complete study for a comprehensive understanding of the impact of genericization on drug prices and treatment value across these 8 countries.
. If the provided articles seems to be less than 200 characters or it is an intro of the author, then try to generate an articles using this title.Impact of genericization on drug prices and treatment value across 8 countries – Healthcare Economist
